Professor of Internal Medicine
Medicine
300 North Ingalls St Suite 2c40
Ann Arbor, Michigan 48109
[email protected]
300 North Ingalls St Suite 2c40
Ann Arbor, Michigan 48109
Available to mentor
Njira Lugogo, MD
Clinical Professor
-
MSDuke University, Durham, 2016
-
MDVirginia Commonwealth University, 1201 E Marshall St., 4th Floor P. O. Box 980565, 2001
-
BSVirginia Polytechnic Institute and State University, Blacksburg, 1996
twitter https://miasthmaresearch.med.umich.edu/ https://scholar.google.com/scholar?hl=en&as_sdt=0%2C23&q=lugogo%2C+n&btnG= https://www.uofmhealth.org/profile/30571/njira-lucia-lugogo-md
-
Lugogo NL, Sumino K, Akuthota P, Burnette AF, Mathur SK, Lindsley AW, Llanos J-P, Marchese C, Cook B, Martin N, Ambrose CS, Emmanuel B. 2024 May; a5374 - a5374.Proceeding / Abstract / PosterA Phase 4, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Tezepelumab in Patients With Severe Asthma, Including Underrepresented Racial and Clinical Groups: Initial Baseline Demographics and Clinical Characteristics From the PASSAGE Study
DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5374 -
Mohan A, Bagheri A, Senn R, Harwood H, Fergan J, Derstine B, Lugogo NL. 2024 May; a5392 - a5392.Proceeding / Abstract / PosterA Real-world Experience With Tezepelumab as the First Biologic Option in Severe Asthma Patients
DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5392 -
Mohan A, Senn R, Harwood H, Derstine B, Fergan J, Bagheri A, Lugogo NL. 2024 May; a5391 - a5391.Proceeding / Abstract / PosterA Real-world Experience on New Starts Versus Biological Switchers for Tezepelumab in Severe Asthma
DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5391 -
Israel E, Chupp GL, Lugogo NL, Llanos J-P, Martin N, Martin N, Ambrose CS, Jackson DJ. 2024 May; a6704 - a6704.Proceeding / Abstract / PosterAsthma Exacerbation Rates as a Function of Biomarker Levels 4 Weeks After Initiation of Tezepelumab Treatment: An Analysis of the NAVIGATOR Study
DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6704 -
Lugogo NL, Peters AT, Chupp GL, Wechsler ME, Caveney S, Martin N, Parikh B, Ambrose CS. 2024 May; a5251 - a5251.Proceeding / Abstract / PosterClinical Responses to Tezepelumab in Patients With Severe, Uncontrolled Asthma, and a History of Nasal Polyps From the NAVIGATOR Study
DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5251 -
Lanz MJ, Pollack M, Gilbert I, Gandhi H, Tkacz J, Lugogo N. 2024 May; a6696 - a6696.Proceeding / Abstract / PosterComparative Burden of Disease Associated With Short-acting Beta 2 -agonist and Systemic Corticosteroid Exposures in US Children, Adolescents, and Adults With Asthma
DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6696 -
Busse W, Castro M, Lugogo NL, O’Byrne PM, Bacharier LB, Xia C, Hardin M, Soliman M, Sacks H, Jacob-Nara JA, Rowe PJ, Deniz Y. 2024 May; a5368 - a5368.Proceeding / Abstract / PosterDupilumab Add-on to Medium-dose Inhaled Corticosteroid (ICS) Increases Odds of Asthma Control and Reduces FeNO Compared With Placebo Add-on to High-dose ICS
DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5368 -
Spahn J, Kaitlin RAG, Lugogo N, Corren J, Maselli DJ, Ambrose CS. 2024 May; a5388 - a5388.Proceeding / Abstract / PosterEffect of Biologics on Biomarkers of Type 2 Inflammation in Asthma: A Review of the Literature
DOI:10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5388
Health Lab
Biologic injections end up being the best treatment for treating severe asthma after having COVID for one patient.
